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Abstract: Fibromyalgia syndrome (FMS) is a widespread pain condition associated with 
a wide range of additional symptoms including fatigue, insomnia, depression, anxiety and 
stiffness. Duloxetine is one of three medications currently FDA approved for use in FMS 
management. Duloxetine is a mixed serotonin and norepinephrine reuptake inhibitor (SNRI) 
that functions by increasing central nervous system levels of serotonin and norepinephrine. 
This review is a primer on use of duloxetine in FMS management and includes information 
on pharmacology and pharmacokinetics, a review of the three duloxetine FMS treatment trials 
currently in publication, a discussion of the safety and tolerability of duloxetine, and patient-
focused perspectives on duloxetine use in FMS management. Duloxetine has proven efficacy in 
managing pain and mood symptoms in adult FMS patients with and without major depressive 
disorder. However, due to side effects, duloxetine must be used with caution in patients with 
fatigue, insomnia, gastrointestinal complaints, headache, cardiovascular disease, bleeding-risk, 
and in those 24 years of age and younger due to risk of suicidality. Duloxetine use should be 
avoided in patients with liver disease or alcoholics. As with all medications, duloxetine is best 
used as part of an individualized regimen that includes nonpharmacologic modalities of exercise, 
education and behavioral therapies.
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Introduction to fibromyalgia management
Fibromyalgia syndrome (FMS) is a disorder of chronic widespread pain (CWP) 
and tenderness associated with a wide range of other symptoms including fatigue, 
nonrestorative sleep, depression, anxiety, and stiffness.1 FMS is a common disorder, 
with published prevalence rates ranging from 0.5% to 5% in countries across the 
world.2 However, these prevalence rates underestimate the true prevalence of the 
disorder as they are based on fulfillment of ACR tender point classification criteria that 
fail to identify nearly 50% of FMS patients, particularly in males who usually have 
fewer tender points.3 Despite the high prevalence of FMS, some clinicians have been 
reluctant to diagnose and treat the disorder based on a belief that the condition is a 
psychogenic disorder with no physiologic basis resulting from the stresses of modern 
life, the feeling that acknowledgement of FMS worsens patient health by reinforcing 
maladaptive coping behaviors and an impression that FMS patients do not improve 
with treatment.4 However, there is evidence that FMS has existed for centuries and is 
prevalent in societies that experience none of the stresses of modernity.5,6 Also, objective 
evidence utilizing numerous modalities has linked FMS to genetic polymorphisms in 
the serotonergic, dopaminergic and catecholaminergic systems of pain transmission and Journal of Pain Research 2009:2 100
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processing that result in multiple neurochemical abnormalities 
including deficient CNS concentrations of serotonin (5-HT) 
and norephinephrine (NE).7,8 Work by Taieb and colleagues 
has shown providing patients with a FMS diagnosis improves 
the health of both patients and the medical system by reducing 
medication use as well as the number of office visits and 
referrals.9 Further evidence for the improvement in FMS 
symptoms with treatment comes from numerous positive 
therapeutic trials and FDA approval of three medications 
for FMS management including duloxetine, milnacipran and 
pregabalin because of their efficacy in improving FMS pain 
and global symptom burden.
While all FMS patients have CWP and tenderness, 
individual patients differ widely in the number and severity of 
other symptoms they experience. This symptom heterogeneity 
requires that each FMS patient be individually assessed 
to identify problematic symptoms and an individualized 
therapeutic regimen be developed to manage each symptom. 
This approach limits treatment failures that often arise from 
an exclusive focus on pain and has been recommended 
by multiple professional societies including the European 
League Against Rheumatism (EULAR).10 However, a 
symptom-based approach is hampered by the inability of 
many patients to effectively articulate their symptom burden 
and the difficulty of clinicians to interpret patient complaints 
into a coherent intellectual framework from which to 
develop a treatment plan. While self-report questionnaires 
to quantify the severity of numerous symptoms exist, their 
length and complexity often preclude use in busy clinical 
practice settings. To overcome these difficulties, one of the 
authors (CSB) has developed the modified visual analogue 
scale fibromyalgia impact questionnaire (mVASFIQ).11,12 
The mVASFIQ utilizes 7 visual analogue scales (VASs) 
from a disease-neutral fibromyalgia impact questionnaire 
(FIQ) in combination with the FIBRO mnemonic to assess 
symptoms of Fatigue (tiredness), Insomnia (sleep quality), 
Blues (mood disorders including depression and anxiety), 
Rigidity (stiffness) and Ow! (for pain and work difficulty). 
This scale provides a simplified global measure of disease 
severity along with individual symptom subscales that can 
be used to individualize therapeutic regimens and monitor 
treatment response.
While a thorough review of FMS management is beyond 
the scope of the current work, many excellent FMS treatment 
reviews exist.10,11,13 Three general points should be kept in 
mind when treating FMS patients. First, primary disorders 
that mimic FMS must be ruled out before symptomatic 
therapies are used including vitamin deficiencies, anemia, 
and metabolic, oncologic or inflammatory disorders. Second, 
since over 50% of FMS patients suffer from multiple medica-
tion intolerances,14 medications should be started individually 
at low dose and slowly up-titrated and/or combined. Also, 
multiple medications or combinations may need to be tried 
before finding a regimen the patient will tolerate. Finally, 
while this review focuses on pharmacologic treatment with 
duloxetine, medications have a limited role in FMS manage-
ment. Medications provide symptom relief so that patients 
can participate in nonpharmacologic modalities that provide 
long-term disease coping strategies.10 Nonpharmacologic 
treatments with proven efficacy in managing FMS involve 
a combination of aerobic and resistance exercise, education, 
and cognitive behavioral therapies.10
Review of pharmacology, mode  
of action, and pharmacokinetics  
of duloxetine
Duloxetine HCl is a mixed serotonin and norepinephrine 
reuptake inhibitor (SNRI), meaning that it acts to increase 
levels of both serotonin and norepinephrine (NE) in the central 
nervous system (CNS).15 This mechanism of activity has been 
verified by measurement of platelet serotonin (5-HT) levels 
and urinary excretion of NE and its metabolites as markers 
of circulating 5-HT and NE.16 Duloxetine is one of a group of 
four FDA approved SNRIs that also includes desvenlafaxine, 
milnacipran and venlafaxine. Although medications in other 
antidepressant classes, such as the tricyclic antidepressants 
(TCAs), monoamine oxidase inhibitors (MAOIs) and high 
doses of the first-generation selective serotonin reuptake 
inhibitors (SSRIs), can also increase both 5-HT and NE levels 
in the CNS, the SNRIs have been shown to be safer and 
better tolerated.17 While all SNRIs increase both 5-HT and 
NE levels, they differ in their ratio of selectivity for 5-HT 
versus NE reuptake inhibition (Table 1).18,19 In vitro data 
shows that duloxetine, with a 5-HT:NE reuptake inhibition 
ratio of 10:1, is intermediate among the SNRIs. While differ-
ences in 5-HT:NE ratios may affect the relative efficacy of the 
SNRIs in treating FMS symptoms, the clinical significance of 
this difference is currently unknown and will require head-
to-head treatment trials. However, it should be noted that 
all SNRIs have 5-HT:NE ratios much more neutral than the 
SSRIs which have ratios between 100 and 2600:1.20
Duloxetine is metabolized mainly through the hepatic 
cytochrome P450 (CYP450) system.21 Because of its exten-
sive hepatic metabolism, duloxetine should ordinarily not 
be prescribed to patients with substantial alcohol use or Journal of Pain Research 2009:2 101
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evidence of chronic liver disease. Smoking lowers serum 
concentrations of many psychotropic medications through 
its effects on CYP1A2, and this causative effect has been 
implicated in a 30% reduction from expected serum con-
centrations in smokers taking duloxetine.22 However, the 
clinical relevance of this altered metabolism in terms of the 
need for dose adjustment remains unclear. The half-life of 
duloxetine in plasma is 12.5 hours and, as with many SSRIs, 
this relatively short half-life presents a risk of withdrawal 
syndrome if the drug is stopped abruptly.15,21 Duloxetine 
clearance decreases with age but not to a degree requiring 
dose adjustment, and gender has no significant effect on 
half-life.23 Taking duloxetine with meals prolongs the time to 
peak plasma concentration by 6 to 10 hours but does not alter 
the peak plasma concentration.21 The prolongation of time to 
peak plasma concentration by taking duloxetine with a meal 
can limit the development of side effects and it is generally 
recommended duloxetine be taken with food. However, 
crushing capsules or otherwise removing the enteric coating 
(such as sprinkling in food) can lead to erratic absorption of 
duloxetine and should be avoided.23 Lilly Research Labora-
tories, the manufacturer of duloxetine, has investigated the 
effects of mixing whole capsules in food products commonly 
used as delivery agents and found that while applesauce and 
apple juice had no effect on enteric capsule integrity, choco-
late pudding hastened the dissolution of duloxetine.24
Duloxetine efficacy studies
Three randomized, double-blind, placebo-controlled 
trials (RCTs) of duloxetine in the treatment of FMS have 
been published to date.25–27 The first was a 12-week trial 
that examined the effect of duloxetine at a dose of 60 mg 
twice daily compared with placebo in male and female 
FMS patients with and without major depressive disorder 
(MDD).25 Subjects were recruited through 5 academic 
centers and 13 “independent research centers” within the US. 
Trial subjects were required to meet ACR classification 
criteria for fibromyalgia including chronic widespread pain 
for 3 months and the presence of at least 11 of 18 tender 
points.1 Exclusion criteria included comorbid psychiatric 
illness other than MDD, treatment-refractory FMS, and 
pending disability review. Fibromyalgia Impact Question-
naire (FIQ) global and individual FIQ VAS pain severity 
scores were the coprimary endpoints. The FIQ is the most 
widely used measure for quantifying the severity of FMS 
symptoms and includes 20 questions that assess functionality 
with activities of daily living (ADL), work difficulty, general 
feelings of well-being, sleep quality and the severity of 
symptoms including pain, fatigue, depression, anxiety, and 
stiffness.28 Secondary endpoints included individual FIQ 
component scores as well as scores on the short form Brief 
Pain Inventory,29 Clinical Global Impression of Severity 
(CGI) (a scale measuring the clinician’s impression of change 
in disease severity ranging from 1 [normal, not at all ill] 
to 7 [among the most extremely ill patients]),30 the Patient 
Global Impression of Improvement scale (PGI) (a scale 
measuring patient response to therapy ranging from 1 [very 
much better] to 7 [very much worse]),30 the Beck Depression 
and Anxiety Inventories (21-question survey of depression or 
anxiety symptoms, respectively),31,32 the Medical Outcomes 
Study Short Form 36 (SF-36), Quality of Life in Depres-
sion Scale, and the Sheehan Disability Scale (SDS). The 
SF-36 contains both physical and mental components to 
assess global patient function.33 The SDS assesses functional 
impairment through use of home, school/work, and social 
domains.34 Eighty-nine percent of the subjects in the study 
were women and 87% were racially classified as white.
While both FIQ global and VAS pain scores showed 
statistically significant improvement in the duloxetine 
treatment group compared with placebo after 4 weeks, this 
improvement was not maintained and, despite significant 
improvement in FIQ global scores occurring in the duloxetine-
treated group at the 12-week time point, the study failed to 
reach its coprimary endpoint due to a lack of demonstrated 
improvement in VAS pain scores at 12 weeks. Since the 
study did not meet its coprimary endpoints, assessment of 
secondary endpoints are not valid. However, the authors 
reported analyses that provide insights for use of duloxetine in 
treating FMS. Most interesting was the finding that no statisti-
cally significant improvement was noted in any of the primary 
or secondary endpoints in male study participants. While this 
lack of  improvement may have been due to the limited number 
of male subjects enrolled in the study (23 in total), gender 
differences in medication response cannot be ruled out. 
Table 1 Relative 5-HT:Ne in-vitro reuptake inhibition of SNRi-active 
drugs
Drug name 5-HT:NE reuptake 
inhibition ratio
venlafaxine 30:118
Duloxetine 10:118
Desvenlafaxine 10:119
Amitriptyline 8:158
Milnacipran 1:118
Abbreviations: 5-HT, serotonin; Ne, norepinephrine; SNRi, serotonin and 
norepinephrine reuptake inhibitor.Journal of Pain Research 2009:2 102
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Also, the low numbers of male participants highlight the 
difficulties inherent in enrolling male subjects in FMS studies 
since the current ACR classification criteria create a 9:1 bias 
in women:men that is much higher than the 4:1 female:male 
ratio seen in our medical center (unpublished results deter-
mined from a search of electronic medical records utilizing 
the Vanderbilt University Record Counter). The female bias 
associated with the ACR criteria is created by the higher 
number of tender points seen in females.35 Male FMS studies 
will likely have to await more gender-neutral revisions of 
the ACR FMS criteria that are currently under development. 
Female subjects treated with duloxetine experienced signifi-
cant improvements as determined by decreased number of 
tender points, increased pain threshold, and improvements in 
CGI-Severity, PGI-Improvement, and BPI scores. However, 
because of the high prevalence of mood symptoms in FMS 
patients and the known association between mood and 
pain, it has been difficult in previous studies to determine 
whether medications are improving pain symptoms due to 
their effect on mood or whether they are improving pain 
symptoms directly. To test the direct effect of duloxetine 
on pain reduction, a path analysis technique was performed 
utilizing three regression models to compare the response 
to mood symptoms (both anxiety and depression) utilizing 
the Beck Inventories to the response to pain that allowed 
estimation of the percentage of direct and indirect effects on 
the total treatment effect.36 The path analysis showed dulox-
etine had a 61% to 83% direct effect on pain improvement 
(depending on which pain scale was being evaluated) that 
was independent of improvement in mood symptoms. This 
finding indicates duloxetine may provide pain relief in FMS 
patients without coexisting mood symptoms. However, this 
study has numerous shortcomings limiting its applicability. 
Duloxetine dose amount and administration in the study dif-
fered from the currently indicated dosing regimen for FMS. 
In the trial, patients were placed on a forced dose titration 
scheme of 20 mg once daily for 5 days, 20 mg twice daily 
for 3 days, 40 mg twice daily for 2 days and 60 mg twice 
daily thereafter. This differs from the recommended dosing 
regimen which is 30 mg once daily for 1 week followed by 
60 mg once daily if patient fails to respond.37 Also, FIBRO 
symptoms such as Fatigue and Insomnia were not studied 
despite both fatigue and insomnia being frequently reported 
treatment-emergent adverse events (TEAEs) with duloxetine 
use in patients with MDD.38
A later 12-week duloxetine RCT studying the effect of 
duloxetine treatment in 354 female FMS patients with and 
without MDD addressed the limitations of the first study and 
provided more clinically applicable conclusions.26 As with the 
first trial, the majority of patients were Caucasian (89.5%), 
with 8.2% classified as ‘Hispanic’ and 2% being of ‘African 
descent.’ Patients were randomized to receive placebo or 
duloxetine 60 mg once or twice daily. The study had a single 
primary outcome measurement which was change in 24 hour 
average pain severity as scored by the BPI VAS.29 A 30% 
improvement from baseline was considered a significant 
response, and multiple secondary endpoints were determined 
including worst and least pain in BPI component scores, 
FIQ global, and mean tender point threshold as measured 
by Fischer dolorimetry. Twenty-six percent of enrollees 
had comorbid MDD, and several scales were included as 
surrogate markers for improvement in depression and for use 
as secondary endpoints including the Hamilton Depression 
rating scale (HAMD17), Quality of Life in Depression Scale, 
SF-36, and SDS. The HAMD17 is a clinician-rated scale that 
includes 17 questions covering mood, sleep, and somatic 
complaints.39 In the trial, both active treatment groups met 
the primary study endpoint with significant improvement 
in pain severity of 37.5% from baseline compared with an 
18.5% improvement in the placebo group. The differences 
between both active treatment groups and placebo were sta-
tistically significant, but there was no difference between the 
once and twice daily duloxetine treatment groups. The same 
pattern of patient response was noted with regard to the FIQ; 
as both duloxetine groups improved to a similar statistically 
significant degree compared with placebo and no significant 
difference was seen between the once- and twice-daily active 
treatment groups. Patients treated with duloxetine at 60 mg 
twice daily showed a statistically significant improvement 
in tender point threshold not seen in the once daily or 
placebo treated groups. However, improvement in tender 
point threshold is a controversial FMS outcome measure 
since tender point threshold measurements are difficult to 
standardize and reproduce consistently,40 pain threshold 
is influenced by patient-independent factors,41 and weak 
to no associations have been found between tender point 
pain ratings and FMS symptoms.42 Overall, the study found 
no significant difference between patients treated with 
duloxetine once or twice daily in any of the other measured 
primary or secondary endpoints. This finding led the authors 
to conclude that the 60 mg twice daily dose provided no 
additional benefit and may expose patients to dose-dependent 
adverse events without improved efficacy, substantiated 
by the current recommended dosing for FMS patients.37 
The symptom improvement with duloxetine treatment was 
rapid, with significant improvements in both pain and FIQ Journal of Pain Research 2009:2 103
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global scores seen within 1 week and reaching a maximum 
within 4 to 6 weeks. However, patients in the trial were 
immediately placed on a daily duloxetine dose of 60 mg 
and the recommended dose escalation protocol using 30 mg 
once daily for 1 week was not used,37 so this rapid response 
may not be seen in routine clinical practice. Consistent with 
the initial duloxetine RCT, Path analysis showed 75.6% 
and 86.9% of the improvement in pain symptoms was due 
to a direct effect of duloxetine on pain at doses of 60 mg 
once and twice daily, respectively, that was independent 
of improvement in depressive symptoms. Further evidence 
for a direct role of duloxetine in providing pain relief was 
provided by data showing patients with and without baseline 
MDD had similar improvements in pain response.
Russell et al published a third RCT to assess the efficacy 
and safety of duloxetine at doses of 20, 60 and 120 mg once 
daily.27 In this study, 520 patients meeting ACR criteria 
for FMS with or without current MDD were treated for 
6 months. The majority of participants were female (94.8%), 
white (84.2%), and averaged 51 years of age. This study used 
a more standard dosing escalation strategy, with patients in 
the 60 mg duloxetine group given 30 mg once daily for the 
first week and patients in the 120 mg group given 30 mg 
once daily for 1 week and then 60 mg daily for 1 week 
before being placed on 120 mg once daily for the remainder 
of the trial. While the trial evaluated patients over 6 months, 
it was actually a 3-month study with a 3-month extension 
phase since the coprimary endpoints of BPI average pain 
severity and PGI-I scores were evaluated at 3 months and 
the 20 mg/day duloxetine group had their dosing increased 
to 60 mg once daily after the initial 3 months. Secondary 
endpoints included BPI and PGI-I scores at 6 months, FIQ 
global, CGI-S, tender-point pain assessments using Fischer 
dolorimetry, the Multidimensional Fatigue Inventory 
(MFI),43 HAMD17, Quality of Life in Depression Scale, 
SF-36 and SDS. Twenty-four percent of study participants 
had comorbid MDD at baseline to determine the effect 
that duloxetine treatment had on this subpopulation. As 
previously discussed, the inclusion of FMS patients with 
MDD is important since approximately 30% of FMS patients 
have MDD.2 The trial met its primary endpoints, with patients 
in both duloxetine 60 mg/day and 120 mg/day treatment 
groups demonstrating statistically greater reductions in pain 
severity and improvements in PGI-I scores after both 3 and 
6 months of treatment compared with placebo. While PGI-I 
scores showed statistical improvement in the 20 mg/day 
duloxetine group, this group failed to meet the coprimary 
endpoint of pain reduction. However, the degree of pain 
reduction was similar to that seen in the 60 mg/day group. 
The lack of statistical significance was likely related to a 
lower statistical power in the 20 mg/day group due to 50% 
fewer patients in this group and not due to lack of efficacy 
in pain relief. This finding, along with findings of similar 
efficacy in improving FIQ global scores, an equally rapid 
statistically significant improvement in pain and PGI-I 
scores, and a lower incidence of TEAEs, indicates serious 
consideration should be made for beginning all FMS patients 
on a 20 mg once daily dose of duloxetine and assessing 
treatment response before dose escalations are made. The 
fact that all groups showed significant improvement after 
one week, during which time all 3 groups were receiving 
either 20 or 30 mg of duloxetine once daily, lends further 
support for the efficacy of lower duloxetine doses. In contrast 
to the first duloxetine RCT,25 the Russell et al study showed 
male and female patients treated with duloxetine had similar 
improvement in the average pain severity after both 3 months 
and 6 months of treatment. Global improvement, as assessed 
by both patient (PGI-I) and clinician (CGI-S) measures was 
significantly improved after both 3 and 6 month time points 
in duloxetine-treated groups as compared with placebo 
(except for the 6 month time point for the PGI-I in the 
60 mg/day group and the CGI-S for the 20 mg/day group at 
3 months). The FIQ score was also significantly improved at 
3 months in all three duloxetine groups compared to placebo, 
but the improvement was lost at 6 months. In contrast to the 
second duloxetine FMS RCT,26 no improvement was seen in 
mean tender-point threshold for any active treatment group 
compared with placebo.
Consistent with both previous discussed studies,25,26 
duloxetine-treated patients experienced similar improvement 
in pain regardless of the presence or absence of MDD, and the 
majority of duloxetine effect on pain was directly mediated 
and not due to improvement in depressive symptoms (from 
62.2 to 82.3% depending on assessment measure and 
dose). Surprisingly, only patients with pre-existing MDD 
treated with 120 mg/day of duloxetine showed improve-
ment in depressive symptoms after 3 months as assessed by 
HAMD17 scores, and no duloxetine dose revealed a clinically 
significant antidepressant effect at 6 months. In contrast to 
the two previously discussed studies, the Russell et al study 
assessed the effect of duloxetine on fatigue symptoms. 
Duloxetine treatment showed similar numeric improvement 
in MFI general fatigue scores at 3 and 6 month end-points 
for all doses, but this improvement was no better than that 
seen with placebo. However, when MFI sub-scores were 
analyzed, patients in all 3 duloxetine treatment groups Journal of Pain Research 2009:2 104
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showed statistically significant improvements in the mental 
fatigue domain (which assesses attention and concentration) 
at the 6 month time point compared with placebo, indicating 
duloxetine may be beneficial in patients with “fibrofog.”
It is important to note that while “treatment refractory” 
patients were excluded from all of the duloxetine RCTs, this 
patient category was not explicitly defined. From a clinical 
perspective, one could consider patients who have not experi-
enced improvement on multiple medications to be refractory, 
and this proportion of fibromyalgia patients has not been 
definitively quantified. However, we are concerned that the 
generalizability of these results to the FMS patient population 
treated by pain specialists may be problematic since these 
patients are typically those who have failed treatment by 
primary care providers. Also, patients with any psychiatric 
comorbidity other than isolated MDD, including MDD with 
coexistent anxiety disorder, were excluded. This would also 
tend to limit broad applicability of the study results since 
comorbid psychiatric diagnoses, particularly the anxiety 
disorders, coexist in approximately 40% of FMS patients.2
Safety and tolerability of duloxetine
The most concise source for data on the safety and tolerability 
of duloxetine comes from a meta-analysis of data from eight 
randomized, double-blind, RCTs on patients with MDD 
included in the initial New Drug Application to the FDA in 
the US and the analogous approval process in the European 
Union.38 Overall, 9.7% (vs 4.2% of placebo group) of patients 
in the RCTs discontinued duloxetine because of TEAEs. 
While these data cannot be directly compared to the FMS 
trials because of different patient populations, study designs 
and durations, similar rates of discontinuation were seen in 
the three duloxetine FMS RCTs.25–27 Nausea was the most 
common TEAE, occurring in 19.9% of duloxetine-treated 
subjects and 6.9% of placebo-treated subjects. Other TEAEs 
occurring at a higher numeric rate in duloxetine-treated 
groups included dry mouth, vomiting, decreased appetite, 
constipation, insomnia, dizziness, fatigue, somnolence, and 
adverse sexual side effects. Since the different dose groups 
within each trial were pooled, analysis of dose-dependent 
side effects from the meta-analysis is limited. However, 
the FMS trials demonstrated similar TEAEs, with nausea, 
dry mouth, and constipation being the three most common 
and occurrences were seen at a numerically higher rate with 
increased duloxetine dose.
Small but statistically significant changes in weight have 
been noted with duloxetine treatment.38 On average, patients 
initially lose 0.46 kg but typically return to baseline weight 
12 weeks after initiation of duloxetine followed by weight 
gain. Weight gain is dose dependent, with the percentage of 
patients gaining 7% of baseline bodyweight numbering 
3.1% on placebo, 8.6% on duloxetine 60 mg/day, and 
12.8% on 120 mg/day. While the initial weight loss correlates 
with the period of maximum rates of nausea, vomiting, and 
decreased appetite, a causal relationship between these 
TEAEs and weight loss has not been established. Average 
time to onset for nausea is typically within one day of treat-
ment with a time to resolution averaging seven days in the 
MDD trials.38
As fatigue and sleep disturbance are often significant 
problems for FMS patients in addition to pain, the side effect 
profile of duloxetine raises concerns about use in these FMS 
patients. Sleep disturbance and fatigue trended toward, but 
did not reach, statistical significance in the Russell et al 
study,27 and a dose-response relationship with somnolence 
symptoms was seen in duloxetine-treated patients in the 
second FMS RCT that reached statistical significance in 
the highest dosage group (60 mg twice daily).26 No specific 
data on the impact of duloxetine on sleep in FMS patients 
is available. However, there have been investigations 
performed in patients with MDD44,45 and diabetic peripheral 
neuropathic pain (DPNP).46 Since MDD and DPNP patients 
frequently experience sleep disturbances and chronic painful 
physical symptoms as manifestations of their disease,47,48 
conclusions drawn from studies of the effect of duloxetine 
on sleep in these patients with MDD may have applicabil-
ity to FMS patients. Polysomnographic studies on subjects 
with MDD taking 60 mg duloxetine once daily showed 
changes in stage 3 and rapid eye movement (REM) sleep, 
including significant increases in Stage 3 sleep duration 
(from 21.0 ± 10.7 to 37.4 ± 20.1 min) and REM latency 
(from 58.5 ± 31.1 to 193.6 ± 72.6 min), and decreased total 
REM sleep (from 94.8 ± 34.5 to 51.5 ± 42.5 min) after 7 to 
13 days of treatment with duloxetine (all times expressed 
as mean ± standard deviation).45 Since restorative sleep 
occurs during stage 3 and 4 sleep, and FMS patients often 
have decreased time spent in these sleep stages, these results 
indicate duloxetine may be beneficial to sleep architecture 
in FMS patients. Unfortunately, the prolongation of stage 3 
sleep was not supported by polysomnographic studies in a 
group of healthy controls treated with duloxetine that found 
similar changes in REM sleep.49 However, this study was 
conducted in males and used higher duloxetine doses (both 
80 mg once daily and 60 mg twice daily), so it may not be 
as valid a comparison to FMS patients. Studies on the effect 
duloxetine has on sleep in FMS patients are needed.Journal of Pain Research 2009:2 105
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Since, polysomnographic data does not always correspond 
to clinically important sleep outcomes, a recent investigation 
of duloxetine treatment in patients with MDD that evaluated 
clinically important sleep outcomes may be more relevant.44 
This study measured sleep disturbance in three insomnia 
categories including early (sleep onset), middle, and late 
(early awakening) utilizing the HAMD17 sleep items and 
spontaneous subjective reports of sleep-related TEAEs. 
Duloxetine-treated subjects had a statistically significant 
improvement in early and late onset insomnia but no 
improvement in middle insomnia. However, the end-average 
HAMD17 insomnia score for duloxetine-treated subjects was 
1.9 vs 2.1 in placebo-treated subjects on a 6-point scale. 
While this difference reached statistical significance, it is 
likely not a clinically relevant change. Also, 6.5% of study 
subjects took other sleep aid medications, which may have 
obscured the clinical impact of duloxetine on sleep. It was 
noted that duloxetine-treated patients had a significantly 
higher rate of TEAEs such as ‘abnormal dreams’ and 
‘hypersomnia’ that correlated with these subjects reporting 
smaller increments of overall sleep improvement. Sleep 
and depression symptom improvement also correlated, 
suggesting sleep enhancement may be due to treatment of 
MDD rather than via a direct beneficial effect of duloxetine 
on sleep. Pooled data from three studies in DPNP patients 
without MDD also suggested duloxetine enhances sleep 
indirectly, as improvement in sleep correlated with reductions 
in pain based on BPI measurements including ratings of pain 
interference with sleep.46 These results excluded patients with 
treatment-emergent somnolence, which could be classified 
as a TEAE. Overall these results are inconclusive for strong 
evidence for or against duloxetine use in FMS patients with 
underlying Insomnia symptoms. Patients treated with dulox-
etine should be informed they may experience sleep-related 
side effects.
Abnormal laboratory value rates were reported in the 
previously discussed meta-analysis of duloxetine MDD 
trials38 and the FMS duloxetine RCTs.25–27 While there were 
some small but statistically significant changes noted, these 
changes were not consistently seen among the trials. Aspartate 
aminotransferase, alanine aminotransferase, alkaline phos-
phatase, and creatine phosphokinase levels all rose to a 
statistically significant degree in at least one of the trials, but 
the investigators determined these changes to be clinically 
nonsignificant since the values remained within normal 
reference ranges. However, the manufacturer recommends 
against use of duloxetine in patients with hepatic insuffi-
ciency or severe alcohol use,37 and we recommend baseline 
measurement of liver enzymes be performed followed by 
periodic monitoring in all patients treated with duloxetine and 
that duloxetine treated patients be counseled to avoid alcohol. 
Statistically significant decreases in serum sodium were noted 
in the Russell et al study,27 but this was deemed clinically 
nonsignificant based on values remaining within normal 
reference ranges. Hyponatremia is a recognized side effect 
of  SSRIs,50 so its occurrence with duloxetine, which has 
serotonergic activity, is not surprising. Therefore, baseline 
and periodic monitoring of basic serum chemistries, including 
sodium, is prudent and recommended.
Anti-depressants and other psychotropic medications are 
known to be associated with cardiac side effects including 
QT prolongation with TCAs and sudden cardiac death 
associated with typical and atypical antipsychotics.51 While 
electrocardiogram (ECG) data were not collected in all of 
the trials included in the pooled data from initial depression 
efficacy trials,38 no significant effect on QT or QTc interval 
was noted and no ECG effects were seen in the duloxetine 
FMS trials.25–27 Duloxetine administration has consistently 
been associated with a statistically significant increase in 
heart rate, systolic and diastolic blood pressure in both 
MDD31 and FMS trials,25–27 but the average increase has been 
uniformly small and not deemed clinically significant when 
considering the data as a whole by any of the investigators. 
However, the actual clinical effect in individual patients, 
especially those with comorbid hypertension or heart disease, 
cannot be predicted based on aggregate data and baseline 
and periodic monitoring of blood pressure and heart rate is 
recommended.37
Also, concerns that increased circulating norepinephrine 
levels induced by duloxetine could negatively affect cardiac 
function and induce harmful cardiac remodeling have been 
voiced,52 implying that duloxetine treatment may negatively 
impact patients with pre-existing congestive heart failure 
(CHF). This concern is supported by case reports of worsening 
heart failure after initiating treatment with venlafaxine53 and 
duloxetine.52 No prospective studies have evaluated the effect 
of duloxetine treatment in patients with CHF.
In addition to possible cardiac side effects, duloxetine 
treatment also presents a theoretical bleeding risk since 
serotonin-active medications are known to decrease platelet 
aggregation,54 and a retrospective data review found a 
statistically significant increased risk of gastrointestinal 
bleeding when SSRIs were used in combination with 
nonsteroidal anti-inflammatory medications (NSAIDs).55 
While pooled data from trials of duloxetine in MDD have 
found no statistically significant increase in bleeding Journal of Pain Research 2009:2 106
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disorders compared to placebo,38 NSAID use is common in 
FMS patients. Since the effect on bleeding risk in individual 
patients cannot be predicted, caution is advised when consid-
ering duloxetine use in patients with a history of gastrointes-
tinal (GI) bleeding or patients taking NSAIDs. Concomitant 
proton pump inhibitor treatment should be considered in 
patients at risk for bleeding complications.
The FDA requires that antidepressant medications, 
including duloxetine, contain a ‘black box warning’ in their 
prescribing information indicating use may increase the risk 
of suicidality. This is because some patients with MDD and 
other psychiatric disorders have developed suicidal ideation 
upon initiating anti-depressant medication therapy. This has 
been theoretically attributed to the stimulating properties of 
these medications that may lead patients to experience an 
increase in energy and motivation before there is resolution of 
other depressive symptoms such as suicidal thoughts. Suicide 
risk is most prominent in patients aged 24 years old or younger 
with 14 additional episodes of suicidality per 1000 patients 
compared to placebo in patients less than 18 years of age 
and 5 additional cases in patients aged 18 to 24 years.37 Data 
imply a more neutral profile for patients 25 to 64 years of 
age, with 1 fewer case for each 1000 patients treated, and 
protective effects were noted in patients 65 years and older 
with 6 fewer cases. However, since individual suicidal risk 
cannot be predicted, all patients should be warned about the 
possible increased risk of suicidality and encouraged to seek 
emergency care if suicidal thoughts occur.
Discontinuation of duloxetine has been associated with 
withdrawal symptoms, including dizziness, nausea, and 
headache in patients who have received the medication to 
treat depression.37 If duloxetine must be discontinued, a slow 
down-titration taper is recommended to minimize withdrawal 
symptoms. If patients experience clinically significant 
symptoms with dose taper, the dosage should be increased 
and then tapered more slowly.37
Patient focused perspectives on use 
of duloxetine in FMS management
Reviewing the three duloxetine FMS treatment trials to 
estimate medication tolerability,25–27 the highest adherence 
rate in the trials was seen in the 60 mg/day duloxetine 
treatment group in the 2005 Arnold et al study,26 with 65% 
of patients completing the 12-week trial. In this RCT, more 
patients in the duloxetine treatment groups completed the 
trial compared with placebo, and more patients treated with 
placebo discontinued the study due to lack of efficacy than 
those treated with duloxetine. This result was statistically 
significant suggesting, not surprisingly, that patients with 
symptom improvement were more likely to continue taking 
duloxetine. Consistent with this result, duloxetine-treated 
patients in the Russell et al study27 were more likely to 
complete the trial compared with placebo-treated patients. 
In contrast, placebo-treated patients in the 2004 Arnold 
et al trial25 were more likely to be compliant than those on 
active drug (64% vs 56%, respectively). The data indicates 
treatment adherence can be increased by dosing strategies 
that maximize both efficacy and tolerability. Since TEAEs 
are known to increase with duloxetine dose, and therapeutic 
efficacy has been seen in patients treated with duloxetine 
20 mg once daily,27 the authors recommend FMS patients 
be started on duloxetine at a dose of 20 mg once daily 
where available and monitored for treatment response for 
at least 1 week before the dose is increased. If patients fail 
to respond, the dose should be increased in 20 mg intervals 
and patient response evaluated before increasing. Because 
of the greater incidence of TEAEs with duloxetine at doses 
of 120 mg/day and the lack of improved efficacy compared 
with duloxetine 60 mg/day,26 patients with FMS should 
not be treated with doses exceeding 60 mg/day to reduce 
the likelihood of discontinuation secondary to adverse 
events.
Based on data from the three duloxetine FMS RCTs 
and duloxetine’s FDA indications for the management of 
both depression and anxiety,25–27,37 duloxetine is most likely 
to benefit middle-aged females with FIBRO symptoms of 
Blues (mood disorders) and Ow! (pain). Furthermore, in the 
Russell et al study,27 all doses of duloxetine significantly 
improved attention and concentration (as measured by 
the MFI mental fatigue domain) suggesting FMS patients 
with cognitive dysfunction (‘fibrofog’) may benefit from 
duloxetine treatment. Patients with FMS are known to 
have Irritable Bowel Syndrome (IBS) with prevalence 
rates estimated between 32% to 80%.56,57 Because the FMS 
RCTs show GI symptoms such as nausea, constipation 
and decreased appetite were more likely to occur in FMS 
patients treated with duloxetine compared with placebo,25–27 
clinicians must use duloxetine with caution in FMS patients 
with IBS. In these individuals, it is especially important to 
use the “start low and go slow” approach with a 20 mg/day 
dose used first since it appears to have the lowest occurrence 
of GI symptoms.27
FMS patients with FIBRO symptoms of Fatigue and 
Insomnia should be warned about the potential for dulox-
etine to exacerbate their symptoms, as insomnia occurred 
more frequently in patients treated with duloxetine Journal of Pain Research 2009:2 107
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compared with placebo.27,37 Furthermore, somnolence 
in all duloxetine-treated groups occurred at twice the 
rate of placebo in the Russell et al study,27 which may 
exacerbate Fatigue symptoms. However, it is important to 
remember that the impact of duloxetine on sleep in FMS 
patients treated with duloxetine has not been thoroughly 
investigated.
Conclusions and key points
•  FMS is a complex disorder best managed utilizing an 
individualized therapeutic regimen that includes both 
pharmacologic and nonpharmacologic treatments that 
addresses the entirety of patient symptoms.
•  The FIBRO mnemonic can be used to recall FMS 
symptoms including Fatigue, Insomnia, Blues, Rigidity, 
and Ow! for pain.
•  Primary disorders that can mimic FMS must be ruled out 
before instituting symptomatic therapies.
•  Pharmacologic treatments should utilize a ‘start low and 
go slow’ approach.
•  Duloxetine is an SNRI medication indicated for the 
management of adult FMS patients at a dose of 60 mg 
once daily, however, lower doses may be effective and 
we recommend starting with a 20 mg once daily dose 
with increases in weekly intervals only if needed.
•  The pain ameliorating effect of duloxetine is independent 
of its effect on mood, however, since it is the only FMS 
medication also indicated to treat MDD and anxiety 
syndrome duloxetine should be the first line therapy in 
FMS patients with coexisting mood disorders.
•  Duloxetine may be particularly beneficial in FMS patients 
with significant cognitive dysfunction (‘fibrofog’), but it 
may worsen symptoms of Fatigue and Insomnia.
•  TEAEs seen in duloxetine trials include nausea, dry 
mouth, vomiting, decreased appetite, constipation, 
insomnia, dizziness, fatigue, somnolence, and adverse 
sexual side effects.
•  Duloxetine may increase suicide risk, particularly in 
patients 24 years and younger, and use is not recom-
mended in those 18 years of age.
•  Duloxetine use has been associated with liver function 
test abnormalities and hyponatremia, therefore, baseline 
and surveillance laboratory monitoring are recom-
mended and patients should be counseled to avoid 
alcohol use.
•  Duloxetine should be used with caution in patients with 
pre-existing cardiovascular disease and/or increased 
bleeding risk.
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